Completed Research: PRACTICE MANAGEMENT RESEARCH
Abstract #CR06

Impact of PGY2 Oncology Pharmacy Residents’ Learning Experiences During the COVID-19 Pandemic

JHOP - March 2022 Vol 12 Special Feature - HOPA Abstracts

Presenter: Yun Man, PharmD, BCOP, Medication Use Quality and Policy Specialist, Dana-Farber Cancer Institute, Boston, MA

Co-Authors: Megan Menon, PharmD, BCOP, Medication Safety Officer, Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY; Lijian Cai, PharmD, Chief Pharmacy Officer, Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY

BACKGROUND: The COVID-19 pandemic caused an unprecedented challenge with supply and demand of staff disruption in the healthcare system.1 The pharmacy residency learning experiences were ultimately affected by the COVID-19 pandemic.2

OBJECTIVE: To evaluate the impact of oncology pharmacy residents’ learning experiences during the COVID-19 pandemic by conducting an inquiry with response measurement from the American Society for Health-System Pharmacists (ASHP)-accredited postgraduate year 2 (PGY2) oncology pharmacy residency programs at National Comprehensive Cancer Network (NCCN) member institutions.

METHODS: We surveyed a stratified sample of ASHP-accredited PGY2 oncology pharmacy residencies at 28 NCCN member institutions through the NCCN Pharmacy Directors Forum. The survey included 43 questions and was delivered to the panel participants. The survey was deployed using the web-based survey tool SurveyMonkey, and targeted oncology pharmacy directors who are involved in PGY2 residency training. The representative of each program had the opportunity to complete the survey or to forward it to an alternative delegate within the program, for completion. Requests to participate were sent through e-mail to the participants. The survey included questions related to the oncology learning experience, pharmacy staffing, educational activities, and onboarding process after the emergence of the COVID-19 pandemic in the United States.

RESULTS: Of the selected 28 residencies that were sent the survey, 17 residencies completed the survey between February 22 and March 19, 2021, resulting in a 60.7% survey response rate. Participating programs mostly have 2 oncology residents and at least 21 oncology pharmacy preceptors. At the time of the survey, 94% of the respondents reported they had no changes in the numbers and duration of the core and elective learning experiences. In all, 82% of the responding programs continued to have residents on the same staffing hours as before the pandemic. As reported by the survey respondents, the activities that were fully transitioned to virtual reporting included educational responsibility (41%), residents–students teaching encounters (11.76%), and conference presentations (87.5%).

CONCLUSION: The oncology pharmacy residency training experience has been affected by the COVID-19 pandemic, with the most significant change reported in shifting the learning experience to a remote format. Flexibility and adaptability are essential for residency programs that are required to undergo rapid structural changes and maintain consistent training experiences for residents.

  1. Welles Sasser C, Wolcott MD, Morbitzer KA, Eckel SF. Lessons learned from pharmacy learner and educator experiences during early stages of COVID-19 pandemic. Am J Health Syst Pharm. 2021;78:872-878.
  2. Moore WJ, Webb A, Morrisette T, et al. Impact of COVID-19 pandemic on training of pharmacy residents and fellows: results from a national survey of postgraduate pharmacy trainees. Am J Health Syst Pharm. 2021;78:1104-1111.
Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: